procyanidin b3 has been researched along with Prostatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, H; Hattori, Y; Katoh, M; Kawaguchi, K; Kawahara, S; Makabe, H; Matsumoto, K; Suda, M; Toda, K | 1 |
| Choi, KC; Lee, YH; Lim, BJ; Na, Y; Naito, S; Park, S; Seong, AR; Shiota, M; Sung, AR; Yokomizo, A; Yoon, HG | 1 |
2 other study(ies) available for procyanidin b3 and Prostatic Neoplasms
| Article | Year |
|---|---|
Syntheses of procyanidin B2 and B3 gallate derivatives using equimolar condensation mediated by Yb(OTf)3 and their antitumor activities.
Topics: Antineoplastic Agents; Biflavonoids; Catechin; Cell Line, Tumor; Gallic Acid; Humans; Male; Mesylates; Organometallic Compounds; Proanthocyanidins; Prostatic Neoplasms | 2013 |
Procyanidin B3, an inhibitor of histone acetyltransferase, enhances the action of antagonist for prostate cancer cells via inhibition of p300-dependent acetylation of androgen receptor.
Topics: Acetylation; Biflavonoids; Catechin; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; E1A-Associated p300 Protein; Histone Acetyltransferases; Humans; Male; Proanthocyanidins; Prostatic Neoplasms; Receptors, Androgen; Transcription, Genetic | 2011 |